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IntroductIon 
Asymmetric dimethylarginine (ADMA) is a nitric oxide (NO) 
synthase inhibitor considered to be a major cardiovascular 
risk factor in the general population (1) and in renal disease 
patients (2), whereas symmetric dimethylarginine (SDMA) 
is thought to be a biologically inactive substance, although 
it competes with l-arginine in its intracellular transport (3). 
Both ADMA and SDMA originate from proteolysis of meth-
ylated proteins (including dietary proteins). They are nor-
mally cleared by urine, but ADMA is also metabolized by 
dimethylarginine dimethylaminohydrolase (DDAH) (4). Thus 
the circulating levels are increased in uremic patients (5, 6), 
and the ADMA/SDMA molar ratio may reflect DDAH activity, 
which seems to be sensitive to oxidative stress and possi-
bly to inflammation. Thereby several factors related to renal 
function, nutrition and inflammation may be important in 
the variability of dimethylarginine serum levels in end-stage 
renal disease (ESRD) patients. Protein-energy malnutrition 
AbstrAct 
Background: Asymmetric dimethylarginine (ADMA) 
and symmetric dimethylarginine (SDMA) originate 
from hydrolysis of methylated proteins, including di-
etary proteins, and are retained in end-stage renal dis-
ease (ESRD). This study aimed to detect the correla-
tion of ADMA and SDMA to nutritional parameters in 
dialysis patients.
Methods: Before and after a single dialysis session, l-
arginine, ADMA and SDMA plasma levels were meas-
ured in 38 hemodialysis patients by HPLC–tandem 
mass spectrometry. Biochemistry, protein intake, an-
thropometry and bioelectric impedance analysis were 
evaluated 
Results: Predialysis plasma levels of ADMA were high-
er than in normal controls (n=20) (1.14 ± 0.27 µmol/L 
vs. 0.56 ± 0.09 µmol/L, p<0.001), as were SDMA levels 
(3.49 ± 1.00 µmol/L vs. 0.44 ± 0.13 µmol/L, p<0.001). 
On univariate analysis, predialysis ADMA levels were 
inversely related to BMI and albumin levels, whereas 
SDMA was directly related to nPNA, phase angle, pre-
albumin and creatinine serum levels. ADMA/SDMA ra-
tio was inversely related to prealbumin and albumin, 
creatinine, urea and phosphorus serum levels, as well 
as nPNA, but positively to C-reactive protein. On mul-
tiple regression analysis, serum albumin and BMI were 
the stronger predictors of ADMA, whereas prealbumin 
serum levels followed by dietary protein intake were 
the stronger predictors of SDMA. Prealbumin followed 
by C-reactive protein was predictive of the ADMA/
SDMA molar ratio.
Conclusions: Our results confirm that ADMA and 
SDMA levels are increased in ESRD patients and 
suggest that a link may exist with inflammation and 
nutritional status. High ADMA levels associated with 
reduced SDMA may be a predictive marker of mal-
nutrition-inflammation-atherosclerosis syndrome.
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is considered a common feature of hemodialysis patients. 
Several cohort studies have revealed that protein-energy 
malnutrition is associated with inflammation and increased 
cardiovascular disease that negatively affect the clinical 
outcome of the hemodialysis population (7). 
Zoccali et al described an inverse relationship between 
serum albumin and ADMA (2), but to our knowledge, no 
study exists dealing with the relationships between ADMA 
or SDMA and a panel of different parameters of nutritional 
status assessment. This cross-sectional study aimed to 
detect the relations between ADMA and SDMA plasma lev-




Thirty-eight patients (25 men, 13 women, mean age 63 ± 
13 years) affected by chronic renal failure stage V, who had 
been on maintenance hemodialysis treatment for at least 
6 months, were selected for this observational study. The 
exclusion criteria were the following: malignancy, inflam-
matory or infectious disease, cachexia, anorexia, severe 
congestive heart failure (NYHA class IV or V), liver failure, 
psychiatric disease, lower limb critical ischemia, parenteral 
nutrition or use of steroids. 
The underlying renal disease was chronic glomerulonephri-
tis in 10 cases, ischemic nephropathy in 8 cases, diabetic 
nephropathy in 6 cases, polycystic renal disease in 3 cas-
es, tubulointerstitial nephritis in 3 cases and unknown in 8 
cases. No patient was being treated with angiotensin-con-
verting enzyme (ACE) inhibitors or angiotensin II receptor 
blockers, whereas nitroglycerine was used in 10 patients 
and calcium channel blockers in 10 cases. Thirty-five out of 
the 38 patients were on erythropoiesis-stimulating agents. 
Some clinical features of the studied population are depict-
ed in Table I.  
Dialysis treatment was performed on a thrice-a-week 
schedule, for 210-270 minutes. The dialysis vintage was 
70 ± 58 months. A native arteriovenous fistula was used as 
vascular access in 33 patients, arteriovenous graft in 3 cas-
es and a permanent central vein catheter in 2 cases. All of 
the patients followed their usual dialysis technique chosen 
on a clinical basis: standard hemodialysis in 12 cases, on-
line hemodiafiltration in 16 cases and acetate-free biofiltra-
tion in 10 cases; high-flux or low-flux synthetic membranes 
(polyamine, polysulphone or AN69) were used. 
Twenty healthy subjects, comparable for sex and age, were 
recruited to form a normal control group regarding ADMA 
and SDMA plasma levels. 
Methods
Before and after a single dialysis session, L-arginine, 
ADMA and SDMA plasma levels were measured. Predi-
alysis biochemistry examinations included serum albumin, 
prealbumin, urea, creatinine, calcium, phosphorus, sodium 
bicarbonate, hematocrit, hemoglobin, C-reactive protein 
(CRP), Kt/V and normalized Protein Nitrogen Appearance 
(nPNA). Body mass index (BMI) was calculated by height 
and postdialysis body weight. Erythropoietin index was 
calculated by the following formula: weekly dose of eryth-
ropoiesis-stimulating agent (ESA) / weight / hemoglobin; 
where weight was in kilograms and hemoglobin in grams 
per deciliter. Values <10 are desirable or normal.  Bioelec-
tric impedance vectorial analysis (BIVA) was performed 30 
minutes after the end of the hemodialysis session (8, 9), 
using a Bioelectrical Impedance Analyzer (BIA/STA; Akern, 
Florence, Italy) with a distal, tetrapolar technique, deliver-
ing an excitation current at 50 kHz; BIVA parameters were 
measured in duplicate.  
BIVA gives 2 bioelectric parameters: body resistance (R) 
and reactance (Xc), and the impedance vector (Z) is a com-
bination of R and Xc across tissues. The arc tangent of Xc/R 
is called the phase angle (PA), which is a derived measure 
obtained from the relation between the direct measures of 
resistance and reactance reflecting hydration status and 
soft tissue cellular mass. Reduced phase angle reflects an 
increased extracellular to intracellular water ratio as well as 
a decrease in body cell mass. It is a predictor of survival  in 
a number of diseases and also in the dialysis population 
(10), where phase angle values lower than 4.0° are associ-
ated with increased mortality risk (11). 
Blood samples were drawn from the arterial line, before the 
beginning of the first dialysis of the week, and at the end 
of the dialysis session using the stop-flow method.  Se-
rum samples were cooled within 1 hour and then stored at 
-20°C until analysis was performed. 
Serum levels of l-arginine, ADMA and SDMA were detect-
ed by high-performance liquid chromatography (HPLC)–
tandem mass spectrometry, using a method strictly derived 
from that proposed by Schwedhelm et al (12). Sample prep-
aration was carried out as follows: 12 µL of a water solution 
containing ADMA-D6 and l-arginine-D7, 2 µM and 200 µM, 
respectively, was added to a 20-µL aliquot of plasma sam-
ple, in a 1.5-mL 12x32 conical vial. After vigorous vortex 
mixing, 868 µL of pure methanol was added, and the mix-
ture was shaken again by vortex. The protein matter was 
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then separated from the liquid solution by centrifugation at 
6,000 rpm, and 60 µL of supernatant was placed into a 96-
well plate, each tube containing 200 µL. The plate content 
was then evaporated to dryness by a gentle stream of nitro-
gen, heating at 65°C. The solid matter was then reconsti-
tuted with 3N HCl in n-butanol (Regis Technologies, Morton 
Grove, IL, USA) used as a derivatization reagent, vortexed, 
incubated 25 minutes in a oven at 65°C and evaporated 
again under nitrogen. The successive reconstitution was 
carried out by 125 µL of a mixture methanol and water 1/1 
(v/v). The calibration curves were built by 7 standard solu-
tions, prepared in the same way as the samples, contain-
ing the analytes in the following concentrations: 375, 750, 
1,500, 3,000 6,000, 12,000 and 24,000 nM for l-arginine; 
3.75, 7.5, 15, 30, 60, 120 and 240 nM for ADMA and SDMA. 
One microliter of either sample and standard solution was 
injected in the HPLC–tandem mass spectrometry system, 
which was constituted of autosampler, column oven, binary 
micro-HPLC pump system (all components; Perkin Elmer, 
Boston, MA, USA) Series 200, and an Applied Biosystems-
MDS Sciex API 4000 triple quadrupole mass spectrometer 
(Concord, Ontario, Canada), equipped with a Turbo-V Ion-
Spray source. HPLC column and conditions were the same 
as described by Schwedhelm et al (12), as well as the mass 
spectrometry selected reaction monitoring transitions. The 
operative parameters resulted as follows: IonSpray voltage, 
5.0 kV; gas source 1, 50; gas source 2, 30; turbo tempera-
ture, 650°C; entrance potential, 10 V; collision gas, nitro-
Fig. 1 - Asymmetric dimethylarginine (ADMA) and symmetric 
dimethylarginine (SDMA) plasma levels in the end-stage renal 
disease patients studied, as recorded before (black column) 
and after (grey column) a hemodialysis session, compared 
with normal control values (empty column); *p<0.001, vs. nor-
mal controls; §p<0.001, vs. after dialysis. 
gen; CAD gas pressure, 3.5 mPa. In addition, declustering 
potentials, collision energies and collision exit potentials 
were optimized for either analytes or standards in order to 
get the best sensitivity.
Statistics
Descriptive statistics are given as means ± standard de-
viation. Statistical analysis was performed by Student’s 
t-test for unpaired and paired data. The Spearman rank 
correlations of plasma ADMA and SDMA were identified 
by univariate and multivariate analysis; forward and back-
ward elimination was used in identifying the most important 
prognostic factors. The statistical package StatView 5 ver-
sion 5.0.1 for personal computer was utilized for process-
ing data. Differences were considered to be statistically 
significant when p<0.05.
results 
Figure 1 shows that predialysis plasma levels of ADMA were 
higher in ESRD patients than in controls (1.14 ± 0.27 µmol/L 
vs. 0.56 ± 0.09 µmol/L, p<0.001), as were levels of SDMA 
(3.49 ± 1.00 µmol/L vs. 0.44 ± 0.13 µmol/L, p<0.001) and 
l-arginine (127 ± 55 µmol/L vs. 56 ± 15 µmol/L, p<0.001). 
ADMA levels were significantly lower than SDMA levels 
(p<0.001) (Fig. 1). Following a single dialysis treatment, se-
rum levels of l-arginine (73 ± 32 µmol/L), ADMA (0.65 ± 
0.17 µmol/L) and SDMA (1.58 ± 0.43 µmol/L) were signifi-
cantly reduced (Fig. 1). 
Table I shows clinical and nutritional features of the studied 
population. Signs of protein-energy malnutrition emerged 
in a small proportion of patients. Namely, BMI <20 kg/m2 
was detected in 10 out the 38 patients (18%), serum albu-
min <3.5 g/dL in 10%, phase angle <4.0° in 26%, nPNA 
<0.8 g/kg per day in 18% and <1.0 g/kg per day in 60%. 
Finally, a proinflammatory status (CRP >5.0 mg/L) was de-
tected in 55% of the studied patients.
On univariate analysis, predialysis ADMA levels were in-
versely related to albumin levels, BMI and body weight 
after dialysis (Tab. II). A stepwise regression model, with 
ADMA as dependent variable, including body weight before 
and after dialysis, BMI and albumin levels showed albumin 
as the strongest independent predictor of ADMA (p=0.01; 
F=6.602), followed by BMI (p<0.01; F=5.633).
SDMA was directly related to nPNA, phase angle, hemo-
globin, hematocrit, prealbumin and urea serum levels (Tab. 
II). A stepwise regression model, with SDMA as dependent 
variable, including nPNA, prealbumin, hematocrit and he-
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pendent predictor of SDMA (p<0.01; F=8.775), followed by 
nPNA (p<0.01; F=5.595). 
Finally, predialysis ADMA/SDMA molar ratio was inversely 
related to prealbumin and albumin serum levels, predialysis 
creatinine, urea and phosphorus serum levels, as well as 
nPNA, but positively to CRP (Tab. II). 
A stepwise regression model, with ADMA/SDMA as de-
pendent variable, including prealbumin levels, nPNA lev-
els, creatinine levels and CRP, showed prealbumin as the 
strongest independent predictor of ADMA/SDMA (p<0.01; 
F=17.813) followed by CRP (p<0.01; F=13.968).
The subgroup of hemodialysis patients with CRP ≥5.0 mg/L 
have higher ADMA/SDMA ratio than patients with CRP <5.0 
mg/L (0.39 ± 0.09 vs. 0.29 ± 0.08, p=0.01). 
dIscussIon 
In ESRD patients, the risk of cardiovascular morbidity and 
mortality is greatly increased (13), due to the coexistence in 
the uremic patient of a number of cardiovascular risk fac-
tors, both traditional and emerging ones, including abnor-
malities of the NO metabolism and endothelial dysfunction 
(14-16). ADMA is an inhibitor of nitric oxide synthase (NOS), 
and increased circulating levels of ADMA are believed to 
TABLE I  
CLINICAL AND BIOCHEMICAL FEATURES OF THE STUDIED PATIENTS
Mean ± SD Median Range 
Age, years 66 ± 14 71 32-85
Dialysis vintage, months 72 ± 59 50 6-216
Body weight postdialysis, kg 63.2 ± 11.4 62.2 43.4-89.5
BMI, Kg/m2 24.1 ± 4.8 22.9 17.7-37.2
Systolic BP, mm Hg 120 ± 27 120 72-170
Diastolic BP, mm Hg 65 ± 12 65 38-88
Mean BP, mm Hg 83 ± 16 84 49-106
Pulse BP, mm Hg 45 ± 24 52 15-95
Kt/V 1.55 ± 0.29 1.53 1.0-2.3
nPNA, g/kg per day 0.95 ± 0.21 0.91 0.52-1.63
Serum calcium, mg/dL 8.9 ± 0.6 8.9 7.2-9.9
Serum phosphorus, mg/dL 4.8 ± 1.7 4.3 2-9
Serum albumin, g/dL 4.2 ± 0.7 4.2 2.7-5.0
Serum prealbumin, mg/dL 33 ± 10 32 14-53
Serum sodium bicarbonate, mM 23.2 ± 1.8 23.5 19-30
Hemoglobin, g/dL 11.4 ± 1.7 11.6 7.4-13.9
EPO resistance 8.5 ± 5.3 9.4 2.3-22.5
Serum urea, mg/dL 133 ± 39 125 63-249
Serum creatinine, mg/dL 9.2 ± 3.1 8.6 2.0-16.0
C-reactive protein, mg/L 8.9 ± 8.1 6.0 1.2-39.1
Phase angle, ° 5.3 ± 1.3 5.2 2.9-7.7
Body cell mass index, kg/m2 7.7 ± 2.6 7.6 3.6-12.5
BMI = body mass index; BP = blood pressure; EPO = erythropoietin ; nPNR = normalized Protein Nitrogen Appearance.
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reduce production and action of NO on vascular endothe-
lium, and thus ADMA is considered to be a novel risk factor 
for vascular disease. 
Our data confirm that dimethylarginines are increased in 
dialysis patients, but ADMA is lower than SDMA, because 
of the additional metabolism by DDAH. 
Some contrasting data exist about the effect of the dialysis 
procedure on ADMA plasma levels. Namely, some authors 
claim low dialysance of ADMA, probably due to significant 
protein binding (17), leading to negligible changes follow-
ing dialysis (5). Some authors suggest that mixed diffu-
sive-convective dialysis techniques are more efficient than 
standard diffusive dialysis in lowering ADMA plasma levels, 
but others have failed to demonstrate any benefit (18). 
TABLE II  
SIGNIFICANT CORRELATIONS OF ADMA, SDMA AND 




  BMI -0.420 <0.01
  Serum albumin -0.440 <0.01




  Hematocrit 0.476 <0.01
  Hemoglobin 0.472 <0.01
  Serum urea 0.402 <0.01
  Phase angle 0.448 <0.01
  nPNA 0.497 <0.01
  Serum prealbumin 0.568 <0.001
ADMA/SDMA
  Serum albumin -0.446 <0.01
  Serum urea -0.466 <0.05
  Serum phosphorus -0.434 <0.01
  Serum creatinine -0.470 <0.01
  nPNA -0.485 <0.01
  Serum prealbumin -0.617 <0.001
  C-reactive protein 0.526 <0.001
ADMA = asymmetric dimethylarginine; BMI = body mass 
index; BP = blood pressure; nPNA = normalized Protein Ni-
trogen Appearance; SDMA = symmetric dimethylarginine.
Our results demonstrate that a significant decrease of l-
arginine and dimethylarginine plasma levels occur follow-
ing a single hemodialysis treatment, and these are well in 
keeping with Bergamini et al (19). Additionally, other au-
thors have found an average decrease in ADMA and SDMA 
levels of 32%  and 44%, respectively, with all hemodialysis 
modalities (20, 21). 
A number of relationships between dimethylarginine plas-
ma levels and parameters of nutritional status and inflam-
mation were shown in the present study. 
ADMA plasma levels were inversely related to albumin lev-
els. Our data are quite different from those of Busch et al 
(22), but they are well in keeping with those of Zoccali et al 
(2), who found a negative association between ADMA and 
serum albumin in a cohort of 250 hemodialysis patients. 
Serum albumin and BMI were strong predictors of ADMA 
serum levels, so it may be speculated that poor nutritional 
status, in particular abnormal protein metabolism, is asso-
ciated with high ADMA levels.  
In contrast, low levels of SDMA are associated with sev-
eral markers of poor nutritional status, namely low pro-
tein intake, low prealbumin and creatinine serum levels 
and low phase angle. The reason may be that SDMA 
production is derived from hydrolysis of methylated pro-
teins, including dietary proteins, and its metabolism is 
not affected by DDAH, but depends on renal excretion 
or dialysis removal. Serum prealbumin and nPNA were 
strong predictors of SDMA serum levels; thus, it is likely 
that the predialysis SDMA levels may be related to pro-
tein catabolic rate and then to dietary protein intake, in 
the stable patient at least. 
ADMA/SDMA ratio may give indirect information about 
the rate of DDAH activity, since only ADMA is metabolized 
by the enzyme. Our data show that ADMA/SDMA  ratio is 
associated with inflammation status and signs of malnu-
trition. A direct relationship was found between ADMA/
SDMA ratio and CRP levels, and patients indicating in-
creased inflammation have significantly higher ADMA/
SDMA ratios. This is well in keeping with the findings that 
inflammation is able to inhibit DDAH activity.  In addition, 
higher ADMA/SDMA ratios were associated with lower 
protein intake, lower prealbumin and albumin serum levels 
and lower predialysis levels of creatinine, urea and phos-
phorus. As a whole, these data suggest that ADMA/SDMA 
ratio is strictly related to nutritional and inflammation in 
dialysis patients; that is to say, Increased ADMA/SDMA 
is suggestive of malnutrition and inflammation. Actually, 
serum prealbumin and CRP were the stronger predictors 
of ADMA/SDMA molar ratio. It could be speculated that 
high ADMA levels together with high ADMA/SDMA ratio 
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may be markers or mediators of the malnutrition-inflam-
mation-atherosclerosis syndrome in uremic patients (7, 
23). Therefore, in addition to reporting ADMA as a potent 
inhibitor of NO synthase and a major factor affecting NO 
metabolism and endothelial functioning, it is important 
also to report SDMA levels. 
The method we used (HPLC–tandem mass spectrometry) 
is the most reliable one, and it allows the measurement of 
ADMA and SDMA at the same time and in the same run. 
However, the cross-sectional design and the small sample 
size were limitations of this study, which prevent us from 
drawing conclusions. 
In summary, ADMA and SDMA plasma levels are increased 
in hemodialysis patients, and ADMA levels are lower than 
SDMA levels, because of additional metabolism by DDAH.
Several associations have been found between plasma 
levels of dimethylarginines and inflammation and nutri-
tional indicators. Increased ADMA levels are associated 
with low BMI and low albumin levels – both markers of 
poor nutrition and possibly of inflammation. Higher SDMA 
levels are associated with markers of good nutritional sta-
tus, namely with higher protein intake, and with higher 
prealbumin serum levels. Serum prealbumin and CRP are 
strong predictors of the ADMA/SDMA molar ratio. As a 
whole ADMA/SDMA seems to be a good predictor of poor 
nutrition and inflammation – that is, high levels of ADMA 
coupled with low SDMA levels in uremic patients may be 
linked to enhanced risk of the malnutrition-inflammation-
atherosclerosis syndrome. This hypothesis needs to be 
confirmed by further investigations. 
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